• Wondering whether Intuitive Surgical stock offers good value at today’s price, or if you might be paying too much for quality.
• The stock last closed at US$449.03, with the share price up 3.9% over the past week, down 3.6% over the past month, down 20.1% year to date, up 48.4% over three years, and up 60.5% over five years.
• Recent coverage of Intuitive Surgical has centered on its position in robotic assisted surgery and how that fits into long term healthcare trends. This helps explain why the stock can move sharply as expectations shift. Broader commentary has also focused on how investors balance the company’s surgical system footprint, installed base, and recurring procedure volumes against what they are willing to pay for the stock today.
• Right now, Intuitive Surgical scores just 1 out of 6 on our valuation checks. The next step is to compare what different methods say about fair value, and then look at a more complete way of thinking about valuation that ties the numbers back to the bigger picture for this stock.

Intuitive Surgical scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Intuitive Surgical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value. It is essentially asking what those future dollars are worth in today’s terms.

For Intuitive Surgical, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $2.32b. Analyst estimates and subsequent extrapolations suggest free cash flow could reach about $6.14b by 2030, with intermediate annual projections between 2026 and 2035 ranging from roughly $4.27b to $8.19b before discounting.

When these projected cash flows are discounted back and added up, the model arrives at an estimated intrinsic value of about $405.86 per share. Compared with the recent share price of $449.03, the DCF output suggests the stock currently trades at about a 10.6% premium to this estimate, so it screens as somewhat expensive on this specific model.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Intuitive Surgical may be overvalued by 10.6%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Intuitive Surgical Price vs Earnings

For a profitable company, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. It helps you see, at a glance, how the market is weighing the company’s earnings power against other opportunities you could invest in.

What counts as a normal or fair P/E depends on how the market views the company’s growth prospects and risks. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk tends to pull the P/E closer to, or below, the market and sector averages.

Intuitive Surgical currently trades on a P/E of 53.38x. That is above the Medical Equipment industry average of 24.98x and also above the peer average of 26.73x. Simply Wall St’s Fair Ratio framework estimates what a more tailored P/E could look like, at 32.24x, based on factors such as earnings growth, industry, profit margins, market cap and company specific risks. Because this approach incorporates more of Intuitive Surgical’s own profile than a simple peer or sector comparison, it is a more rounded benchmark. On this basis, the current P/E is higher than the Fair Ratio, which indicates that the stock screens as expensive on earnings.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Intuitive Surgical Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page give you a clear story that links your view of Intuitive Surgical’s business to specific forecasts for revenue, earnings and margins, then to a Fair Value you can compare with today’s share price. Each Narrative updates automatically when fresh news or earnings arrive, and different investors sometimes land far apart, such as one valuing the stock around US$325.55 per share and another closer to US$750.00. This shows how the same company can support very different yet structured opinions about whether the current price looks high or low.

For Intuitive Surgical however we will make it really easy for you with previews of two leading Intuitive Surgical Narratives:

Fair value: US$532.46

Price vs fair value: about 15.7% below this narrative fair value

Revenue growth assumption: 12%

• Focuses on Intuitive Surgical’s history in robotic assisted surgery and the evolution of the da Vinci platform from early prototypes to the latest da Vinci 5 system.
• Highlights the global installed base of systems and the importance of recurring revenue from instruments, services, and software as a key part of the business model.
• Frames the stock as high quality with valuation seen as tight to fair value, so entry price and expected return assumptions are central to the thesis.

Fair value: US$325.55

Price vs fair value: about 37.9% above this narrative fair value

Revenue growth assumption: 12%

• Emphasises catalysts such as broader adoption of robotic surgery, procedure growth across more specialties, and recurring revenue from instruments and services.
• Sets out industry tailwinds like demand for minimally invasive surgery, along with headwinds that include high system costs, regulatory uncertainty, competition, and reliance on the da Vinci platform.
• Views the stock as priced at a premium, with concerns that any slowdown in growth, margin pressure, or stronger competition could lead to valuation pressure.

Do you think there's more to the story for Intuitive Surgical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.